Quantbot Technologies LP Purchases New Stake in AstraZeneca PLC (NASDAQ:AZN)

Quantbot Technologies LP purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, Holdings Channel reports. The institutional investor purchased 77,776 shares of the company’s stock, valued at approximately $6,060,000.

A number of other large investors have also added to or reduced their stakes in the company. McClarren Financial Advisors Inc. grew its holdings in shares of AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca in the second quarter worth $26,000. Capital Performance Advisors LLP purchased a new stake in AstraZeneca in the third quarter worth $28,000. Pathway Financial Advisers LLC bought a new position in AstraZeneca in the first quarter worth $29,000. Finally, CANADA LIFE ASSURANCE Co lifted its position in AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the period. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AZN shares. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Stock Performance

NASDAQ AZN opened at $66.40 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a market cap of $205.88 billion, a P/E ratio of 31.77, a P/E/G ratio of 1.20 and a beta of 0.47. The business’s 50 day moving average price is $73.19 and its 200-day moving average price is $77.72.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the business posted $0.87 EPS. Sell-side analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.